StockIQpro
NASDAQ:RNAZ

Transcode Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Transcode Therapeutics, Inc. reported net income of −$34.7M in fiscal 2025. Free cash flow was −$19.5M, and the diluted share count rose 5392.2%.Summary generated from Transcode Therapeutics, Inc.'s SEC filings. Latest annual report filed Apr 15, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−833.5%
Debt / equityn/a
Free cash flow−$19.5M
FCF marginn/a
Share count change+5392.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−6−19−19−16−28
Net income−7−18−19−17−35
Free cash flow−6−16−18−13−20

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations